The most relevant benefit of ICIs in NSCLC was observed in those patients characterized by high PD-L1 expression (≥50%) on tumor cells (47) since it facilitates ICIs’ efficacy by increasing tumor visibility, and together with high TMB, provokes a stronger T cell-mediated immune response. This evidence concerns the gene CD274 and non-small cell lung carcinoma.